1–10 of 24 results for Fluocinolone
Three-Year Outcomes of the PALADIN Phase IV Study: Comparison of Anatomical Metrics, Efficacy, and Treatment Burden Post FAc
Christopher D. Riemann, MD
Annual Meeting Talks
2022
Injectable Fluocinolone Implant for the Management of Chronic Postsurgical Uveitis and Cystoid Macular Edema
On Demand Cases, Courses, and Papers
Fluocinolone Intravitreal Implant in Patients With Macular Edema Due to Retinal Vein Occlusion
Ashkan M. Abbey, MD, FASRS, FAAO
2021
Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients
Victor Hugo Gonzalez, MD
Diabetic Retinopathy Progression in Anti-VEGF Versus Fluocinolone Acetonide Implant Treated Eyes Who Are Lost to Follow-up
Caesar K. Luo, MD, FASRS
2020
Course of Macular Edema Through 36 Months With Fluocinolone Acetonide Intravitreal Insert for Non-infectious Uveitis Affecting the Posterior Segment
Seenu M. Hariprasad, MD
Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis following an Injectable Fluocinolone Acetonide Insert
Dilraj S Grewal, MD, FASRS
Variability of Retinal Thickness in Diabetic macular edema (DME) Patients Treated with 0.19mg Fluocinolone Acetonide (FAc, ILUVIEN).
2019
Inflammatory and Infectious Diseases Symposium
Diabetic Retinopathy Progression in Anti-VEGF versus Fluocinolone Acetonide Implant Treated Eyes Who are Lost to Follow-up
Updates from the Field